XORTX Other Current Liab vs Long Term Debt Analysis

XRTX Stock  USD 1.19  0.03  2.59%   
XORTX Therapeutics financial indicator trend analysis is more than just analyzing XORTX Therapeutics current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether XORTX Therapeutics is a good investment. Please check the relationship between XORTX Therapeutics Other Current Liab and its Long Term Debt accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

Other Current Liab vs Long Term Debt

Other Current Liab vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of XORTX Therapeutics Other Current Liab account and Long Term Debt. At this time, the significance of the direction appears to have very week relationship.
The correlation between XORTX Therapeutics' Other Current Liab and Long Term Debt is 0.28. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of XORTX Therapeutics, assuming nothing else is changed. The correlation between historical values of XORTX Therapeutics' Other Current Liab and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of XORTX Therapeutics are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Other Current Liab i.e., XORTX Therapeutics' Other Current Liab and Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.28
Relationship DirectionPositive 
Relationship StrengthVery Weak

Other Current Liab

Long Term Debt

Long-term debt is a debt that XORTX Therapeutics has held for over one year. Long-term debt appears on XORTX Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on XORTX Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.
Most indicators from XORTX Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into XORTX Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.Selling General Administrative is likely to drop to about 996.5 K in 2024. Issuance Of Capital Stock is expected to grow at the current pace this year
 2021 2022 2023 2024 (projected)
Reconciled Depreciation17.9K55.5K139.7K146.7K
Research Development669.1K6.5M2.4M1.6M

XORTX Therapeutics fundamental ratios Correlations

-0.070.820.98-0.27-0.99-0.50.530.990.90.990.760.620.340.891.0-0.35-0.43-0.740.910.22-0.620.560.97-0.150.97
-0.070.35-0.13-0.750.140.00.35-0.14-0.14-0.14-0.16-0.08-0.20.14-0.060.0-0.050.21-0.17-0.55-0.410.28-0.120.25-0.09
0.820.350.8-0.51-0.81-0.140.440.810.60.810.350.240.220.770.83-0.09-0.17-0.340.62-0.3-0.50.370.810.190.84
0.98-0.130.8-0.23-0.98-0.490.390.980.880.980.710.610.440.80.98-0.38-0.45-0.750.920.19-0.580.560.93-0.170.99
-0.27-0.75-0.51-0.230.20.41-0.33-0.21-0.31-0.21-0.14-0.35-0.35-0.31-0.260.210.280.25-0.310.190.56-0.52-0.150.19-0.29
-0.990.14-0.81-0.980.20.44-0.51-1.0-0.88-1.0-0.73-0.57-0.32-0.88-0.990.310.380.7-0.89-0.230.54-0.48-0.980.12-0.97
-0.50.0-0.14-0.490.410.44-0.36-0.43-0.72-0.43-0.77-0.98-0.61-0.37-0.470.690.760.87-0.76-0.580.77-0.87-0.310.8-0.48
0.530.350.440.39-0.33-0.51-0.360.510.550.510.670.38-0.330.830.52-0.15-0.23-0.30.330.28-0.570.440.580.110.34
0.99-0.140.810.98-0.21-1.0-0.430.510.881.00.730.570.320.890.99-0.3-0.37-0.70.880.23-0.540.480.98-0.110.97
0.9-0.140.60.88-0.31-0.88-0.720.550.880.880.880.790.460.80.88-0.4-0.48-0.870.920.55-0.630.70.83-0.340.85
0.99-0.140.810.98-0.21-1.0-0.430.511.00.880.730.570.320.890.99-0.3-0.37-0.70.880.23-0.540.480.98-0.110.97
0.76-0.160.350.71-0.14-0.73-0.770.670.730.880.730.820.20.740.74-0.59-0.65-0.780.780.62-0.720.770.7-0.350.65
0.62-0.080.240.61-0.35-0.57-0.980.380.570.790.570.820.620.470.6-0.7-0.77-0.910.850.57-0.780.850.45-0.780.6
0.34-0.20.220.44-0.35-0.32-0.61-0.330.320.460.320.20.62-0.040.32-0.38-0.41-0.630.660.19-0.310.460.14-0.750.5
0.890.140.770.8-0.31-0.88-0.370.830.890.80.890.740.47-0.040.89-0.18-0.27-0.540.680.22-0.580.460.930.080.78
1.0-0.060.830.98-0.26-0.99-0.470.520.990.880.990.740.60.320.89-0.35-0.42-0.710.890.18-0.610.540.97-0.130.97
-0.350.0-0.09-0.380.210.310.69-0.15-0.3-0.4-0.3-0.59-0.7-0.38-0.18-0.350.990.49-0.53-0.170.75-0.77-0.20.53-0.36
-0.43-0.05-0.17-0.450.280.380.76-0.23-0.37-0.48-0.37-0.65-0.77-0.41-0.27-0.420.990.58-0.61-0.20.83-0.84-0.270.56-0.43
-0.740.21-0.34-0.750.250.70.87-0.3-0.7-0.87-0.7-0.78-0.91-0.63-0.54-0.710.490.58-0.91-0.620.61-0.71-0.60.65-0.73
0.91-0.170.620.92-0.31-0.89-0.760.330.880.920.880.780.850.660.680.89-0.53-0.61-0.910.38-0.680.70.79-0.530.92
0.22-0.55-0.30.190.19-0.23-0.580.280.230.550.230.620.570.190.220.18-0.17-0.2-0.620.38-0.070.260.2-0.480.11
-0.62-0.41-0.5-0.580.560.540.77-0.57-0.54-0.63-0.54-0.72-0.78-0.31-0.58-0.610.750.830.61-0.68-0.07-0.94-0.470.39-0.58
0.560.280.370.56-0.52-0.48-0.870.440.480.70.480.770.850.460.460.54-0.77-0.84-0.710.70.26-0.940.38-0.480.54
0.97-0.120.810.93-0.15-0.98-0.310.580.980.830.980.70.450.140.930.97-0.2-0.27-0.60.790.2-0.470.380.040.91
-0.150.250.19-0.170.190.120.80.11-0.11-0.34-0.11-0.35-0.78-0.750.08-0.130.530.560.65-0.53-0.480.39-0.480.04-0.21
0.97-0.090.840.99-0.29-0.97-0.480.340.970.850.970.650.60.50.780.97-0.36-0.43-0.730.920.11-0.580.540.91-0.21
Click cells to compare fundamentals

XORTX Therapeutics Account Relationship Matchups

XORTX Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets1.1M2.3M17.3M12.3M5.5M5.0M
Other Current Liab641.5K728.4K229.0K151.4K87.6K83.2K
Total Current Liabilities1.3M1.0M4.2M1.5M294.9K280.2K
Total Stockholder Equity(211.7K)1.3M13.1M7.0M4.6M3.1M
Property Plant And Equipment Net731.0341.00.092.5K23.9K28.8K
Net Debt(7.8K)(171.3K)(14.8M)(10.3M)(3.4M)(3.6M)
Retained Earnings(6.8M)(8.0M)(7.6M)(14.1M)(23.7M)(22.5M)
Accounts Payable607.4K305.8K324.0K1.3M195.8K186.0K
Cash58.6K171.3K14.8M10.4M3.4M3.6M
Non Current Assets Total272.7K234.3K1.5M1.5M1.4M731.9K
Cash And Short Term Investments58.6K171.3K14.8M10.4M3.4M3.6M
Net Receivables15.5K14.4K40.7K81.8K60.7K35.1K
Common Stock Shares Outstanding595.5K740.4K1.1M1.5M2.0M2.1M
Liabilities And Stockholders Equity1.1M2.3M17.3M12.3M5.5M5.0M
Other Stockholder Equity683.0K0.05.0M(2.1M)5.8M6.1M
Total Liab1.3M1.0M4.2M5.4M825.9K784.6K
Total Current Assets815.2K2.1M15.8M10.9M4.1M4.2M
Short Long Term Debt Total272.5K43.3K50.8K77.4K11.5K10.9K
Intangible Assets272.4K234.3K201.0K199.4K175.3K189.0K
Net Tangible Assets(484.1K)1.0M16.5M9.2M10.6M11.1M
Net Invested Capital(160.9K)1.3M16.7M7.0M4.6M4.6M
Net Working Capital(484.5K)1.0M14.9M9.4M3.8M4.3M
Other Current Assets741.2K1.9M1.0M379.6K560.4K701.0K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.